Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May 1;80(3-4):371–378. doi: 10.1038/sj.bjc.6690365

Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis

A P Costa-Pereira 1, T G Cotter 1
PMCID: PMC2362321  PMID: 10408840

Abstract

Despite expressing both Fas and Fas ligand, DU145 and LNCaP prostate cancer cells were resistant to anti-Fas-induced cell death. Resistance to Fas-mediated cytotoxicity could be overcome in DU145, but not in LNCaP, cells by pretreating cells with sublethal doses of cytotoxic drugs, such as camptothecin. Activated caspases were shown to be required for this cytotoxicity. Indeed, poly(ADP-Ribose) polymerase was shown to be proteolytically cleaved in cells treated with camptothecin plus anti-Fas, but not in cells treated with anti-Fas only. Moreover, pretreatment of cells with ZVAD completely blocked camptothecin-mediated Fas-induced apoptosis. Sensitization of cells to Fas-induced cell death did not involve up-regulation of Fas or FasL, and it was independent of alterations in the cell cycle. Reactive oxygen intermediates (ROI) have been shown to be important mediators of drug-induced apoptosis. Here, we demonstrate that treatment of DU145 cells with camptothecin, anti-Fas, or both, did not alter the intracellular levels of peroxide or superoxide anion. © 1999 Cancer Research Campaign

Keywords: apoptosis, prostate cancer, Fas, caspases, reactive oxygen intermediates

Full Text

The Full Text of this article is available as a PDF (564.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buttke T. M., Sandstrom P. A. Oxidative stress as a mediator of apoptosis. Immunol Today. 1994 Jan;15(1):7–10. doi: 10.1016/0167-5699(94)90018-3. [DOI] [PubMed] [Google Scholar]
  2. Carter B. S., Carter H. B., Isaacs J. T. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate. 1990;16(3):187–197. doi: 10.1002/pros.2990160302. [DOI] [PubMed] [Google Scholar]
  3. Chung L. W. The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv. 1995;23:33–42. [PubMed] [Google Scholar]
  4. Clément M. V., Stamenkovic I. Superoxide anion is a natural inhibitor of FAS-mediated cell death. EMBO J. 1996 Jan 15;15(2):216–225. [PMC free article] [PubMed] [Google Scholar]
  5. Denmeade S. R., Lin X. S., Isaacs J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 1996 Apr;28(4):251–265. doi: 10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  6. Eischen C. M., Kottke T. J., Martins L. M., Basi G. S., Tung J. S., Earnshaw W. C., Leibson P. J., Kaufmann S. H. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 1997 Aug 1;90(3):935–943. [PubMed] [Google Scholar]
  7. Enari M., Talanian R. V., Wong W. W., Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature. 1996 Apr 25;380(6576):723–726. doi: 10.1038/380723a0. [DOI] [PubMed] [Google Scholar]
  8. Figueroa J. A., Lee A. V., Jackson J. G., Yee D. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. J Clin Endocrinol Metab. 1995 Dec;80(12):3476–3482. doi: 10.1210/jcem.80.12.8530586. [DOI] [PubMed] [Google Scholar]
  9. Friesen C., Herr I., Krammer P. H., Debatin K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996 May;2(5):574–577. doi: 10.1038/nm0596-574. [DOI] [PubMed] [Google Scholar]
  10. Gorman A. M., Samali A., McGowan A. J., Cotter T. G. Use of flow cytometry techniques in studying mechanisms of apoptosis in leukemic cells. Cytometry. 1997 Oct 1;29(2):97–105. [PubMed] [Google Scholar]
  11. Gorman A., McGowan A., Cotter T. G. Role of peroxide and superoxide anion during tumour cell apoptosis. FEBS Lett. 1997 Mar 3;404(1):27–33. doi: 10.1016/s0014-5793(97)00069-0. [DOI] [PubMed] [Google Scholar]
  12. Green D. R. A Myc-induced apoptosis pathway surfaces. Science. 1997 Nov 14;278(5341):1246–1247. doi: 10.1126/science.278.5341.1246. [DOI] [PubMed] [Google Scholar]
  13. Herr I., Wilhelm D., Böhler T., Angel P., Debatin K. M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 1997 Oct 15;16(20):6200–6208. doi: 10.1093/emboj/16.20.6200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hsiang Y. H., Lihou M. G., Liu L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989 Sep 15;49(18):5077–5082. [PubMed] [Google Scholar]
  15. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J. L., Schröter M., Burns K., Mattmann C. Inhibition of death receptor signals by cellular FLIP. Nature. 1997 Jul 10;388(6638):190–195. doi: 10.1038/40657. [DOI] [PubMed] [Google Scholar]
  16. Isaacs W. B., Carter B. S., Ewing C. M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 1991 Sep 1;51(17):4716–4720. [PubMed] [Google Scholar]
  17. Kasahara Y., Iwai K., Yachie A., Ohta K., Konno A., Seki H., Miyawaki T., Taniguchi N. Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. Blood. 1997 Mar 1;89(5):1748–1753. [PubMed] [Google Scholar]
  18. Kroemer G. Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution. Cell Death Differ. 1997 Aug;4(6):443–456. doi: 10.1038/sj.cdd.4400266. [DOI] [PubMed] [Google Scholar]
  19. Lennon S. V., Martin S. J., Cotter T. G. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif. 1991 Mar;24(2):203–214. doi: 10.1111/j.1365-2184.1991.tb01150.x. [DOI] [PubMed] [Google Scholar]
  20. Longthorne V. L., Williams G. T. Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J. 1997 Jul 1;16(13):3805–3812. doi: 10.1093/emboj/16.13.3805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mahler C., Denis L. Management of relapsing disease in prostate cancer. Cancer. 1992 Jul 1;70(1 Suppl):329–334. doi: 10.1002/1097-0142(19920701)70:1+<329::aid-cncr2820701322>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  22. McGahon A. J., Costa Pereira A. P., Daly L., Cotter T. G. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol. 1998 Jun;101(3):539–547. doi: 10.1046/j.1365-2141.1998.00745.x. [DOI] [PubMed] [Google Scholar]
  23. McGowan A. J., Bowie A. G., O'Neill L. A., Cotter T. G. The production of a reactive oxygen intermediate during the induction of apoptosis by cytotoxic insult. Exp Cell Res. 1998 Jan 10;238(1):248–256. doi: 10.1006/excr.1997.3853. [DOI] [PubMed] [Google Scholar]
  24. McGowan A. J., Fernandes R. S., Verhaegen S., Cotter T. G. Zinc inhibits UV radiation-induced apoptosis but fails to prevent subsequent cell death. Int J Radiat Biol. 1994 Oct;66(4):343–349. doi: 10.1080/09553009414551281. [DOI] [PubMed] [Google Scholar]
  25. McGowan A. J., Ruiz-Ruiz M. C., Gorman A. M., Lopez-Rivas A., Cotter T. G. Reactive oxygen intermediate(s) (ROI): common mediator(s) of poly(ADP-ribose)polymerase (PARP) cleavage and apoptosis. FEBS Lett. 1996 Sep 2;392(3):299–303. doi: 10.1016/0014-5793(96)00838-1. [DOI] [PubMed] [Google Scholar]
  26. Müller M., Strand S., Hug H., Heinemann E. M., Walczak H., Hofmann W. J., Stremmel W., Krammer P. H., Galle P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997 Feb 1;99(3):403–413. doi: 10.1172/JCI119174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Nagata S. Apoptosis by death factor. Cell. 1997 Feb 7;88(3):355–365. doi: 10.1016/s0092-8674(00)81874-7. [DOI] [PubMed] [Google Scholar]
  28. Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li-Weber M., Richards S., Dhein J., Trauth B. C. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 1992 May 25;267(15):10709–10715. [PubMed] [Google Scholar]
  29. Owen-Schaub L. B., Radinsky R., Kruzel E., Berry K., Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 1994 Mar 15;54(6):1580–1586. [PubMed] [Google Scholar]
  30. Rokhlin O. W., Bishop G. A., Hostager B. S., Waldschmidt T. J., Sidorenko S. P., Pavloff N., Kiefer M. C., Umansky S. R., Glover R. A., Cohen M. B. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 1997 May 1;57(9):1758–1768. [PubMed] [Google Scholar]
  31. Schulze-Osthoff K., Krammer P. H., Dröge W. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J. 1994 Oct 3;13(19):4587–4596. doi: 10.1002/j.1460-2075.1994.tb06780.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Villunger A., Egle A., Kos M., Hartmann B. L., Geley S., Kofler R., Greil R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 1997 Aug 15;57(16):3331–3334. [PubMed] [Google Scholar]
  33. Widmann C., Gibson S., Johnson G. L. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J Biol Chem. 1998 Mar 20;273(12):7141–7147. doi: 10.1074/jbc.273.12.7141. [DOI] [PubMed] [Google Scholar]
  34. Wyllie A. H., Kerr J. F., Currie A. R. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251–306. doi: 10.1016/s0074-7696(08)62312-8. [DOI] [PubMed] [Google Scholar]
  35. Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med. 1989 May 1;169(5):1747–1756. doi: 10.1084/jem.169.5.1747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. van den Dobbelsteen D. J., Nobel C. S., Schlegel J., Cotgreave I. A., Orrenius S., Slater A. F. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. J Biol Chem. 1996 Jun 28;271(26):15420–15427. doi: 10.1074/jbc.271.26.15420. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES